Travere Therapeutics (TVTX) Jefferies Global Healthcare Conference 2026 summary

Strategic portfolio expansion and innovation

• Acquired rights to civorebrutinib, a BTK inhibitor, to develop for multiple immune-driven rare kidney diseases, complementing existing therapies and expanding reach to underserved patient populations.

• FILSPARI continues strong uptake as the first non-immunosuppressive therapy for IgA nephropathy and recently received approval for FSGS, with broad indications including pediatric patients and all FSGS types without nephrotic syndrome.

• Reinitiated phase III enrollment for pegtibatinase in classical homocystinuria (HCU), aiming to address a significant unmet need in metabolic disease.

• Business development remains a priority, with ongoing disciplined evaluation of new opportunities to drive both near- and long-term growth.

• Strong financial position supports current operations and future pipeline expansion, with no near-term capital needs.

Product performance and market dynamics

• FILSPARI has seen rapid uptake in both IgA nephropathy and FSGS, driven by strong clinical data, broad label, and high unmet need, especially in pediatric and urgent FSGS cases.

• Early launch feedback from nephrologists and payers is positive, with high first-pass approval rates and broad access anticipated, mirroring success in IgA nephropathy.

• FILSPARI is the leading prescribed therapy for IgA nephropathy, with continued growth despite emerging competitors, and only about 10% of the addressable market reached so far.

• Most new FILSPARI patients are upgraded from ACE/ARB therapies, with minimal switching from other approved drugs; combination therapy is expected to increase.

• Sales team expansion has optimized reach to both adult and pediatric nephrologists, supporting ongoing and future launches.

Clinical development and regulatory updates

• Civorebrutinib offers a differentiated, oral, covalent reversible BTK inhibitor profile, with applicability in diseases where FILSPARI is not approved, such as PMN and minimal change disease.

• Phase III pegtibatinase trial in HCU is enrolling, with top-line data expected in the second half of next year; the trial targets reduction in total homocysteine and long-term safety.

• Recent notice of allowance for a method of use patent on FILSPARI in IgA nephropathy could extend exclusivity to October 2037, with similar applications pending for FSGS.

• KDIGO guidelines support combination therapy and early intervention, reinforcing FILSPARI’s foundational role even as new therapies enter the market.

• Ongoing education efforts target both nephrologists and payers to ensure appropriate patient identification and access, especially regarding nephrotic syndrome definitions.